Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

3 weeks ago 24

Vandita Jadeja

Thu, April 30, 2026 astatine 9:40 AM CDT 4 min read

Quick Read

AbbVie (ABBV) reported Q1 gross of $15B, beating statement by $280M, portion Skyrizi surged 30.9% YoY to $4.48B and Rinvoq grew 23.3% to $2.12B.
Management raised full-year adjusted EPS guidance to $14.08-$14.28, and the company’s migraine franchise posted beardown maturation with Qulipta up 53.6% and Ubrelvy up 41.4%.
AbbVie’s post-Humira modulation is moving arsenic aggregate maturation franchises accelerate simultaneously, with an obesity pipeline campaigner showing aboriginal objective payment and valuation compressed backmost to tenable levels aft a 9.3% YTD decline.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.

Our AbbVie (NYSE:ABBV) telephone lands connected the constructive broadside of the ledger aft a noisy but encouraging Q1 net report. The 24/7 Wall St. terms people for AbbVie is $229.32, implying 12.47% upside from the caller adjacent of $203.89.

We complaint ABBV a bargain with precocious assurance (90%), driven by Skyrizi and Rinvoq momentum, raised guidance, and a guardant aggregate that has compressed backmost into tenable territory.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.

24/7 Wall St. Price Target Summary

Metric

Value

Current Price	$203.89
24/7 Wall St. Price Target	$229.32
Upside	12.47%
Recommendation	BUY
Confidence Level	90%

Q1 Results: Headline Noise, Underlying Strength

ABBV is down 9.3% twelvemonth to day and 3.54% implicit the past month, sitting astir 4% beneath the $239.13 52-week high.

Q1 2026 gross came successful astatine $15 billion, beating the $14.72 cardinal statement and increasing 12.43% YoY. Adjusted EPS of $2.65 missed by $0.02, but a $744 cardinal IPR&D complaint clipped $0.41 per share.

Management raised full-year adjusted EPS guidance to $14.08 to $14.28. Shares responded constructively, closing up 3.14% connected the net report.

The Case for $250+

The bull lawsuit rests connected AbbVie's post-Humira pivot already working. Skyrizi grew 30.9% YoY to $4.48 billion, Rinvoq grew 23.3% to $2.12 billion, and the migraine franchise is connected occurrence (Qulipta +53.6%, Ubrelvy +41.4%).

The pipeline adds optionality: a non-incretin obesity candidate, ABBV-295, showed clinically meaningful assemblage value simplification successful aboriginal data, and Elahere posted a >60% nonsubjective effect complaint successful platinum-sensitive ovarian cancer.

The Wall Street statement people sits astatine $249.27 with 22 bargain ratings and zero sells. Our bull-case script reaches $253.25, a 24.21% full return.

The Risks Worth Watching

Humira fell 38.6% YoY to $688 million, Imbruvica slid 24.7%, and the FDA issued a Complete Response Letter connected trenibotulinumtoxinE implicit manufacturing.

Read Entire Article